The original success of Sildenafil undeniably transformed the drug landscape, but investing in companies strongly reliant on off-patent versions presents a challenging picture. Despite early returns were impressive, the end of patents and the appearance of cheaper alternatives have diminished sales. Therefore, a thorough analysis of ongoing income